Nottingham University Hospitals NHS Trust

Phase 3 TERZO Trial to Evaluate Duvelisib in Rare T-Cell Lymphoma Following Promising Phase 2 Results

3 months ago

• The upcoming TERZO trial will assess duvelisib against standard chemotherapy in patients with nodal T-cell lymphoma with follicular helper T phenotype, addressing a significant treatment gap in rare lymphomas. • Phase 2 PRIMO study demonstrated promising results with duvelisib showing a 48% overall response rate and 33.3% complete response rate in relapsed/refractory PTCL patients. • The TERZO trial aims to enroll 124 patients across EU and UK, with progression-free survival as the primary endpoint, potentially leading to regulatory approval if successful.

Amivantamab and Lazertinib Combination Significantly Extends Progression-Free Survival in NSCLC

8 months ago

• A combination of amivantamab and lazertinib demonstrated a 40% improvement in halting lung cancer progression compared to standard treatment, offering new hope for patients. • The Phase 3 trial involved over 1,000 patients with advanced non-small cell lung cancer (NSCLC), showing an average progression-free survival of 23.7 months with the drug combination. • The treatment targets EGFR mutations, which are more prevalent in women and non-smokers, marking a significant advancement in precision medicine for lung cancer. • FDA approved in August, this drug combination represents a crucial step forward, potentially improving survival rates and quality of life for lung cancer patients.

Landmark Clinical Trials of 2024: Promising Advances in Cancer, Malaria, and Genetic Diseases

a year ago

• AstraZeneca's trastuzumab deruxtecan shows a 73.3% intracranial response rate in breast cancer patients with brain metastases, offering a potential new treatment option. • Oxford University's malaria vaccine, R21/Matrix-M, demonstrates a 78% efficacy rate in young African children, marking a significant improvement over existing vaccines. • Verve Therapeutics' VERVE-101/VERVE-102 utilizes in vivo base-editing to deactivate the PCSK9 gene mutation, potentially providing a one-time treatment for high cholesterol. • A Netherlands Cancer Institute study suggests that neoadjuvant ipilimumab and nivolumab may eliminate the need for surgery in stage III melanoma patients, with a 72% positive response.

Savana Leverages AI to Transform EHR Data into Actionable Clinical Insights

4 years ago

• Savana's AI-powered platform analyzes unstructured electronic health record data across 14 countries in five languages, enabling unprecedented access to real-world clinical evidence. • The company's technology has demonstrated significant value during COVID-19 pandemic through the BigCOVIData study, revealing key insights about disease characteristics and predictive factors. • Using advanced Natural Language Processing and privacy-preserving techniques, Savana helps pharmaceutical companies and researchers unlock previously inaccessible clinical data while maintaining patient confidentiality.